Copy
Check out the new Companies-to-Follow List for 2023
CRISPR Medicine News |  15 Feb. 2023
Base Editors | Off-target | Delivery | CAR-TTrials | Microbiome | Advertising | Webinars
UK Medicines Regulator Awards Innovation Passport to Base-Editing Candidate for Heart Disease

Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) by the UK Medicines and Healthcare products Regulatory Agency. VERVE-101 is designed as a single-dose cure for HeFH, and is currently being evaluated in the heart-1 trial in the UK ad New Zealand.

By: Karen O'Hanlon Cohrt - Feb. 15, 2023

Read the article here...
 
Selected Articles 
Clinical Trial Update - Encouraging Safety and Efficacy Data From Phase 1 TALEN Trial in Multiple Myeloma
A Gene-Edited Cell Therapy for an Incurable Disease
Gene-Editing Clinical Trials: Highlights of 2022
Overview: Diseases That Gene Editors Potentially Could Cure
Events 2023

CRISPR - Genome Editing in Medicine and Agriculture

Date: April 16, 2023

Venue Site:
The David Lopatie Conference Centre, Weizmann Institute of Science, Israel

CAR T Cell Therapy and Advances in Cellular Engineering

Dates: June 6-7, 2023

Venue Site:
Oticon salen, Technical University of Denmark, 2800 Lyngby, Denmark

Advertise on CMN in 2023
Thank you for now - more great reads are on the way!
And if you have questions or suggestions, you can reach out to us directly at:
TheEditor@crisprmedicinenews.com
We love hearing from readers!

Happy Reading!

The CMN Team

LinkedIn
Twitter
Copyright © 2023 CRISPR Medicine News, All rights reserved.

Our mailing address is:
TheEditor@crisprmedicinenews.com

Access to CMN Newsletter archive using this link

Want to unsubscribe from these emails?
Unsubscribe from this list.